195 related articles for article (PubMed ID: 27723225)
1. A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial.
Grunberger G; Chen L; Rodriguez A; Tinahones FJ; Jacober SJ; Bue-Valleskey J;
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():34-42. PubMed ID: 27723225
[TBL] [Abstract][Full Text] [Related]
2. Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action.
Jacober SJ; Prince MJ; Beals JM; Hartman ML; Qu Y; Linnebjerg H; Garhyan P; Haupt A
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():3-16. PubMed ID: 27723228
[TBL] [Abstract][Full Text] [Related]
3. Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
Cusi K; Sanyal AJ; Zhang S; Hoogwerf BJ; Chang AM; Jacober SJ; Bue-Valleskey JM; Higdon AN; Bastyr EJ; Haupt A; Hartman ML
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():50-58. PubMed ID: 27723227
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1.
Garg S; Dreyer M; Jinnouchi H; Mou J; Qu Y; Hartman ML; Rosilio M; Jacober SJ; Bastyr EJ;
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():25-33. PubMed ID: 27393697
[TBL] [Abstract][Full Text] [Related]
5. Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.
Davies MJ; Russell-Jones D; Selam JL; Bailey TS; Kerényi Z; Luo J; Bue-Valleskey J; Iványi T; Hartman ML; Jacobson JG; Jacober SJ;
Diabetes Obes Metab; 2016 Nov; 18(11):1055-1064. PubMed ID: 27349219
[TBL] [Abstract][Full Text] [Related]
6. Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study.
Garg S; Selam JL; Bhargava A; Schloot N; Luo J; Zhang Q; Jacobson JG; Hoogwerf BJ
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():43-49. PubMed ID: 27393722
[TBL] [Abstract][Full Text] [Related]
7. Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4.
Blevins T; Pieber TR; Colón Vega G; Zhang S; Bastyr EJ; Chang AM;
Diabetes Obes Metab; 2016 Nov; 18(11):1072-1080. PubMed ID: 27234693
[TBL] [Abstract][Full Text] [Related]
8. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.
Ginsberg H; Cariou B; Orchard T; Chen L; Luo J; Bastyr EJ; Bue-Valleskey J; Chang AM; Ivanyi T; Jacober SJ; Hoogwerf BJ
Diabetes Obes Metab; 2016 Nov; 18(11):1089-1092. PubMed ID: 27486125
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3.
Bergenstal RM; Lunt H; Franek E; Travert F; Mou J; Qu Y; Antalis CJ; Hartman ML; Rosilio M; Jacober SJ; Bastyr EJ;
Diabetes Obes Metab; 2016 Nov; 18(11):1081-1088. PubMed ID: 27265390
[TBL] [Abstract][Full Text] [Related]
10. Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5.
Buse JB; Rodbard HW; Trescoli Serrano C; Luo J; Ivanyi T; Bue-Valleskey J; Hartman ML; Carey MA; Chang AM;
Diabetes Care; 2016 Jan; 39(1):92-100. PubMed ID: 26577417
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.
Harris C; Forst T; Heise T; Plum-Mörschel L; Watkins E; Zhang Q; Fan L; Garhyan P; Porksen N
Diabetes Technol Ther; 2017 Aug; 19(8):463-470. PubMed ID: 28817342
[TBL] [Abstract][Full Text] [Related]
12. Open-label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin-naïve Asian patients with type 2 diabetes.
Hirose T; Cai Z; Yeo KP; Imori M; Ohwaki K; Imaoka T
J Diabetes Investig; 2018 Jan; 9(1):100-107. PubMed ID: 28371567
[TBL] [Abstract][Full Text] [Related]
13. Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials.
Rosenstock J; Marre M; Qu Y; Zhang S; Bastyr EJ; Prince MJ; Chang AM
Diabetes Obes Metab; 2016 Nov; 18(11):1093-1097. PubMed ID: 27484021
[TBL] [Abstract][Full Text] [Related]
14. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
Owens DR; Traylor L; Mullins P; Landgraf W
Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788
[TBL] [Abstract][Full Text] [Related]
15. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
16. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
[TBL] [Abstract][Full Text] [Related]
17. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
[TBL] [Abstract][Full Text] [Related]
18. Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin.
Dailey GE; Gao L; Aurand L; Garg SK
Diabetes Obes Metab; 2013 Dec; 15(12):1085-92. PubMed ID: 23683002
[TBL] [Abstract][Full Text] [Related]
19. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.
Orchard TJ; Cariou B; Connelly MA; Otvos JD; Zhang S; Antalis CJ; Ivanyi T; Hoogwerf BJ
Cardiovasc Diabetol; 2017 Jun; 16(1):73. PubMed ID: 28587667
[TBL] [Abstract][Full Text] [Related]
20. Gender-based differences in glycaemic control and hypoglycaemia prevalence in patients with type 2 diabetes: results from patient-level pooled data of six randomized controlled trials.
Kautzky-Willer A; Kosi L; Lin J; Mihaljevic R
Diabetes Obes Metab; 2015 Jun; 17(6):533-540. PubMed ID: 25678212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
